BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 18631401)

  • 1. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers.
    Quong J; Eppenberger-Castori S; Moore D; Scott GK; Birrer MJ; Kueng W; Eppenberger U; Benz CC
    Breast Cancer Res Treat; 2002 Dec; 76(3):221-36. PubMed ID: 12462383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies.
    Milosevic J; Klinge J; Borg AL; Foukakis T; Bergh J; Tobin NP
    BMC Cancer; 2013 Oct; 13():473. PubMed ID: 24119434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
    Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
    J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
    Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiles of progesterone receptor loss in human breast tumors.
    Creighton CJ; Kent Osborne C; van de Vijver MJ; Foekens JA; Klijn JG; Horlings HM; Nuyten D; Wang Y; Zhang Y; Chamness GC; Hilsenbeck SG; Lee AV; Schiff R
    Breast Cancer Res Treat; 2009 Mar; 114(2):287-99. PubMed ID: 18425577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
    Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
    Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
    Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
    Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
    Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
    Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
    J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
    Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
    Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer.
    Liang X; Lu B; Scott GK; Chang CH; Baldwin MA; Benz CC
    Mol Cell Endocrinol; 1998 Nov; 146(1-2):151-61. PubMed ID: 10022773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.